WGS
GeneDx Holdings Corp.
$62.43
-1.42
(-2.22%)
Mkt Cap
1.85B
Volume
936,420
52W Range
32.21-170.87
Sector
Healthcare
Beta
1.91
EPS (TTM)
-2.66
P/E Ratio
-178.16
Revenue (TTM)
442.68M
Rev Growth (5Y)
+19.0%
EPS Growth (5Y)
N/A
Company Description
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M | 196.17M |
| Net Income | (21.02M) | (52.29M) | (175.77M) | (548.98M) | (245.39M) | (241.34M) | (29.70M) |
| EPS | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -33.16 | -4.26 |
| Free Cash Flow | 14.26M | (33.99M) | (185.86M) | (333.48M) | (211.22M) | (125.10M) | (34.18M) |
| FCF / Share | 0.53 | -1.26 | -7.64 | -32.58 | -64.49 | -22.23 | -6.08 |
| Operating CF | 33.28M | (28.50M) | (180.15M) | (319.15M) | (190.43M) | (93.13M) | (18.73M) |
| Total Assets | 570.19M | 419.38M | 418.76M | 545.26M | 554.09M | 251.64M | N/A |
| Total Debt | 151.95M | 116.17M | 119.77M | 77.13M | 32.85M | 43.26M | N/A |
| Cash & Equiv | 105.00M | 85.21M | 99.68M | 137.40M | 400.57M | 108.13M | N/A |
| Book Value | 308.18M | 245.25M | 228.02M | 253.71M | 388.10M | 4.39M | N/A |
| Return on Equity | -0.07 | -0.21 | -0.77 | -2.16 | -0.63 | -55.00 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.25M | 120.99M | 116.74M | 102.69M | 87.11M | 95.64M | 76.87M | 70.51M | 62.42M | 57.42M | 53.30M | 48.71M |
| Net Income | (63.32M) | (17.67M) | (7.63M) | 10.81M | (6.53M) | 5.44M | (8.31M) | (29.17M) | (20.24M) | (25.77M) | (42.29M) | (46.72M) |
| EPS | -2.16 | -0.61 | -0.27 | 0.38 | -0.23 | 0.20 | -0.31 | -1.10 | -0.78 | -0.99 | -1.64 | -1.84 |
| Free Cash Flow | (38.86M) | (7.44M) | 9.60M | 8.05M | 4.05M | (6.23M) | (5.04M) | (5.86M) | (16.86M) | (32.23M) | (41.09M) | (56.26M) |
| FCF / Share | -1.32 | -0.28 | 0.33 | 0.28 | 0.14 | -0.23 | -0.19 | -0.22 | -0.65 | -1.24 | -1.59 | -2.21 |
| Operating CF | (32.41M) | (3.09M) | 15.77M | 10.42M | 10.18M | (3.18M) | (4.39M) | (4.50M) | (16.41M) | (29.86M) | (40.98M) | (53.50M) |
| Total Assets | 506.30M | 570.19M | 493.90M | 463.86M | 446.43M | 419.38M | 408.84M | 389.10M | 394.53M | 418.76M | 417.29M | 476.39M |
| Total Debt | 168.19M | 151.95M | 113.16M | 114.39M | 114.84M | 116.17M | 116.10M | 116.96M | 123.21M | 119.77M | 73.62M | 75.34M |
| Cash & Equiv | 93.92M | 105.00M | 95.97M | 74.12M | 99.70M | 85.21M | 57.89M | 56.08M | 83.67M | 99.68M | 87.39M | 156.66M |
| Book Value | 254.12M | 308.18M | 292.26M | 277.13M | 257.40M | 245.25M | 204.50M | 194.04M | 207.22M | 228.02M | 254.26M | 296.11M |
| Return on Equity | -0.25 | -0.06 | -0.03 | 0.04 | -0.03 | 0.02 | -0.04 | -0.15 | -0.10 | -0.11 | -0.17 | -0.16 |
WGS News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGS
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
WGS DEADLINE: The Gross Law Firm Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action Deadline
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm